A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
Infectious Diseases and Therapy (2022) - Comments
pubmed: 35618953  doi: 10.1007/s40121-022-00644-6  issn: 2193-8229  issn: 2193-6382 

Giovanni Landoni, Lorenzo Piemonti, Antonella D’Arminio Monforte, Paolo Grossi, Alberto Zangrillo, Enrico Bucci, Marcello Allegretti, Giovanni Goisis, Elizabeth M. Gavioli, Neal Patel, Maria De Pizzol, Georgea Pasedis, Flavio Mantelli